FDA to Remove 12 Popular Peptides from the Category 2 Do Not Compound List Frier Levitt FDA Peptide Update 2026: Removal from Do Not Compound List and What It Means for Pharmacies FDA Compliance for Peptide Therapy and BPC 157 Holt Law The FDA scheduled a hearing on peptides and the implications could be significant for prescribers and FDA Moves on Peptides: What Compounding Pharmacies Need to Know The FDA scheduled a hearing on peptides and the implications could be significant for prescribers and clinics. With BPC 157, TB 500, and others under 503A review, questions around compounding, compliance, and what is FDA Is Diving Deeper in GMP Compliance for Compounding Pharmacies A Follow up Lachman Consultant Services, Inc.